Dec 20, 2024, 22:35 | Blog

Jennifer S. Buell: Transforming cancer care through innovation in immuno-oncology

Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, posted the following on…

Dec 13, 2024, 16:45 | Insight

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Agenus and Tanner Pharma announced a collaboration to provide expanded access to botensilimab (BOT) and…

Dec 6, 2024, 10:17 | Blog

Dhan Chand: Excited to be presenting at the Global Cancer Movement conference today

Dhan Chand, Vice President of Research at Agenus, reshared a post on LinkedIn by OncoDaily,…

Nov 17, 2024, 07:39 | Blog

Dhan Chand: Collaboration and innovation in cancer treatment at SITC 2024

Dhan Chand, Vice President of Research at Agenus, posted on LinkedIn: “Curing cancer requires more than innovative…

Nov 8, 2024, 12:37 | Positive

Jennifer Buell: Pioneering Leadership in Biotechnology

Dr. Jennifer Buell is a prominent figure in the biotechnology industry, currently serving as the…

Nov 2, 2024, 15:51 | Immune Oncology,Immunotherapy

Immunotherapy for Metastatic Colon Cancer: Types, Success Rate, Side Effects & More

Immunotherapy has emerged as a promising treatment option for colon cancer, particularly for patients with…

Oct 29, 2024, 21:00 | Positive

Steven O'Day: At the Forefront of Immunotherapy

Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…

Oct 25, 2024, 16:34 | Insight

Three decades of pioneering in Immune Oncology - Agenus

Agenus Inc. is a biopharmaceutical company and a prominent leader in the field of immuno-oncology,…

Oct 22, 2024, 18:29 | Immune Oncology

Immunotherapy for Colon Cancer: Types, Success Rate, Side Effects & More

Immunotherapy is emerging as a significant treatment option for colon cancer, particularly for patients with…

Oct 7, 2024, 15:21 | Positive

Agenus CEO Dr. Garo Armen Honored with WITSA Eminent Person 2024 Award for Cancer Immunotherapy Breakthrough

Dr. Garo Armen, CEO and Chairman of Agenus Inc., Massachusetts-based leading immuno-oncology biotech, has been…

Sep 24, 2024, 16:52 | Blog

Assessment of the safety and efficacy of Balstilimab in combination with Botensilimab for NSCLC - Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn: ''Assessment of the safety and efficacy…

Sep 15, 2024, 00:29 | Insight

Breelyn Wilky on botensilimab and balstilimab for refractory sarcomas at ESMO24

Agenus shared on LinkedIn: “Breelyn Wilky, presented new data at ESMO24 highlighting the potential of…

Sep 14, 2024, 09:43 | Insight

Article of the day, September 14th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…

Sep 10, 2024, 13:38 | Insight

Agenus‘s latest data from the clinical trial of BOT/BAL in refractory sarcomas at ESMO24

Agenus shared on LinkedIn: “The Agenus team is headed to Barcelona for ESMO24. This Friday,…

Sep 4, 2024, 11:47 | Dialogues

Dr. Benjamin Schlechter on Botensilimab: Practice-changing Drug | Most Promising Cancer Drugs 2024

In this episode of OncoDaily Interviews, Dr. Benjamin Schlechter, a distinguished medical oncologist at the…

Aug 10, 2024, 13:39 | Insight

Botensilimab’s effectiveness against tumours poorly responsive to conventional immunotherapy

Justin Stebbing shared a post on LinkedIn: “Congratulations to Dhan Chand and the Agenus team…

Aug 10, 2024, 11:58 | Insight

Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy

In the rapidly evolving landscape of oncology, we are witnessing remarkable advancements in various treatment…

Aug 9, 2024, 07:16 | Blog

Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers

Botensilimab is an investigational human Fc-enhanced CTLA-4 blocking antibody designed to boost both innate and…

Jul 29, 2024, 06:38 | Blog

Heart of a Warrior: Jennifer’s Triumphant Fight Against Cancer

Jennifer's story is a testament to strength and resilience. Faced with limited treatment options, she…

Jul 19, 2024, 02:00 | Blog

I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan

"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…

Jul 18, 2024, 15:20 | Drugs

Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO

Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…

Jul 13, 2024, 09:41 | Insight

IMMONC - Immune Oncology Research Institute's Experience in Advancing Clinical Cancer Research in Armenia

Cancer affects people across the world regardless of their socioeconomic status. However, low- and middle-income…

Jul 8, 2024, 12:29 | Drugs

Jennifer Buell: NCI Announces Availability of Botensilimab for Clinical Development

Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics, shared on X: “NCI Announces…

Jul 5, 2024, 15:53 | Drugs

Gevorg Tamamyan: Waiting to see promising bot/bal results from our lung cancer trial

Gevorg Tamamyan posted on LinkedIn: "Just saw the presentation from ESMO GI Annual Congress and the…

Jul 1, 2024, 16:15 | Blog

We need to hurry up, because cancer and patients cannot wait!

Gevorg Tamamyan, the Editor-in-chief of OncoDaily and CEO of Immune Oncology Research Institute, shared on…

Jun 30, 2024, 04:58 | Blog

Victor Moreno: Botensilimab and balstilimab in treating heavily pre-treated patients with MSS mCRC

Victor Moreno, Director of Clinical Research at START Madrid-FJD, shared a post on LinkedIn: .…

Jun 29, 2024, 11:05 | Societies

Neoadjuvant botensilimab and balstilimab in colorectal cancer

Smitha Krishnamurthi, Gastrointestinal medical oncologist at Cleveland Clinic, shared on X: "Neoadjuvant botensilimab (1 dose)…

Jun 28, 2024, 15:58 | Insight

Updates on BOT/BAL from ESMOGI24

ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…

Jun 28, 2024, 13:48 | Insight

Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24

Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…

Jun 28, 2024, 13:41 | Insight

New data from the NEST clinical trial was presented at ESMOGI24 - Agenus

Agenus shared on their X page: "New data from the NEST clinical trial was presented…

Jun 28, 2024, 13:09 | Insight

Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC

Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…

Jun 28, 2024, 13:00 | Insight

Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer

Cathy Eng shared on X/Twitter: "Bot/Bal immunotherapy in colon cancer NEST 1/2. Agenus with very…

Jun 17, 2024, 11:39 | Insight

Bot/bal in relapsed refractory MSS metastatic colorectal cancer - a quick summary

Arndt Vogel shared a post on X: "Botensilimab plus balstilimab in relapsed/refractory MSS mCRC. Phase…

Jun 15, 2024, 02:09 | Insight

Anthony El-Khoueiry: Botensilimab with expansion in MSS CRC; activity noted across multiple cold tumors

Anthony El-Khoueiry, Associate Professor of Medicine at University of Southern California Norris Comprehensive Cancer Center,…

Jun 14, 2024, 01:23 | Insight

New Paper Alert! Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab

Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab Authors: Andrea J. Bullock,…

Jun 13, 2024, 23:58 | Insight

Steven O'Day shared the latest data and insights from our botensilimab programs - Agenus

Agenus shared on LinkedIn: "Yesterday, our Chief Medical Officer, Dr. Steven O'Day, joined clinical experts…

Jun 13, 2024, 17:33 | Insight

Agenus' Phase 1 clinical trial results have been published in Nature

Agenus shared their publication on investigational immunotherapeutic agents in Nature: "Results from our Phase 1…

Jun 10, 2024, 16:17 | Blog

Steven O’Day will be presenting an update on botensilimab programs at Nature Conferences’s event - Agenus

Quoting Agenus on X: "Tomorrow, Dr. Steven O’Day will be speaking at Nature Conferences’ Cancer Immunotherapy…

May 17, 2024, 11:18 | Drugs

Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA

Agenus shared on LinkedIn: “Today we announced that Agenus has been granted a Type B…

May 16, 2024, 16:51 | Insight

10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily

In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…

May 12, 2024, 03:08 | Blog

CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals

Agenus shared on LinkedIn: “‘With this infusion of capital, we are poised to accelerate the…

Apr 28, 2024, 05:36 | Societies

Agenus selected for a poster presentation at the American Society of Clinical Oncology's ASCO2024 Annual Meeting

Quoting Agenus's post on LinkedIn: "Mark your calendars! We have been selected for a poster…

Apr 13, 2024, 06:43 | Opinion

Agenus announced updated Phase 1 data and progress botensilimab/balstilimab combination in metastatic MSS colorectal cancer

Agenus shared on LinkedIn: "Today we announced updated Phase 1 data and progress on our investigational…

Mar 26, 2024, 15:02 | Insight

Pashtoon Kasi: With BOT/BAL in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks

Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine shared on LinkedIn: "We…

Feb 21, 2024, 12:05 | Insight

Pashtoon Kasi: See the discussion on our NEST-1trial by Rachna Shroff and Shaalan Beg

Pashtoon Kasi, the Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X/Twitter:…

Feb 14, 2024, 14:59 | Blog

Yelena Janjigian is leading the investigator-initiated trial of the First Novel Combination of MiNK's Allogeneic Cell Therapy with Agenus' BOT/BAL

Today MiNK Therapeutics released an announcement of the First Refractory Gastric Cancer Patient Dosed in…

Feb 14, 2024, 13:40 | Insight

Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer

Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn: "Happy to share…

Jan 31, 2024, 14:14 | Blog

Elad Sharon: The hottest new ICI BOTENSILIMAB in Kidney Cancer

Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Michael Serzan, Genitourinary…

Jan 28, 2024, 16:11 | Drugs

Michael Serzan: About the hottest new ICI BOTENSILIMAB in Kidney Cancer?

Michael Serzan, Genitourinary Medical Oncologist from Dana-Farber Cancer Institute, shared on X: " Interested in…

Jan 27, 2024, 15:39 | Blog

Agenus joined oncology leaders from across the globe at ASCO GI (GI24)

Agenus recently posted on their LinkedIn page: "Agenus joined oncology leaders from across the globe…

Jan 20, 2024, 14:14 | Drugs

Pashtoon Kasi: Are we on the verge of a new drug combo for colon or rectal cancer?

Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X: "🆕🗞️Just…

Dec 20, 2023, 09:57 | Blog

Pashtoon Kasi: Our paper with more than 10,000 accesses ranks at N1 in Oncogene Journal

Pashtoon Kasi, the Director for Colorectal Cancer Research at Weill Cornell Medicine, shared on X:…

Nov 3, 2023, 12:10 | Drugs

Steven O'Day shared their recent webinar presented by Endpoints News on “The Next I-O Revolution”

Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn: ''Did you catch our…

Oct 24, 2023, 14:05 | Drugs

Agenus is proud to unveil the latest research from our investigational botensilimab programs - Agenus

Agenus shared a post on LinkedIn: "Agenus is proud to unveil the latest research from…

Oct 23, 2023, 15:23 | Drugs

Pashtoon Kasi: So excited to move the field forward with novel therapies for patients with pMMR/MSS Colorectal Cancer

Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital, shared on his Twitter:…

Oct 23, 2023, 13:31 | Drugs

At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma

Agenus shared on their LinkedIn page: "At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational…

Oct 15, 2023, 19:05 | Blog

Steven O'Day: I am thrilled to be joining Dr. Benjamin Schlechter, Dr. Pashtoon Kasi, and Phuong Ly-Gallagher for an engaging discussion on “The Next I-O Revolution”.

Sep 25, 2023, 16:07 | Insight

Steven O'Day: Today is World Cancer Research Day, which is a good day for me to share three things.

Quoting Steven O'Day, the Chief Medical Officer at Agenus, on LinkedIn: "Today is World Cancer…

Sep 24, 2023, 18:03 | Blog

Pashtoon Murtaza Kasi: The imagery at RareCyte Incorporated will blow your mind.

Quoting Pashtoon Murtaza Kasi, Oncologist and Researcher at Weill Cornel Medicine and New York- Presbyterian…

Sep 21, 2023, 11:16 | Drugs

Pashtoon Kasi: Are we on the verge of a new drug combo for colorectal cancer?

Pashtoon Kasi, the Director of Colon Cancer Research at Weill Cornell Medicine, shared on X/Twitter:…

Jul 1, 2023, 06:00 | Drugs

Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer

In a post by Agenus on Linkedin, it says, "ESMO Late-Breaking GI Data: Agenus’ botensilimab/balstilimab…